Nicole White
Corporate Officer/Principal chez ASSEMBLY BIOSCIENCES, INC.
Fortune : 174 014 $ au 30/04/2024
Profil
Nicole S.
White is currently the Chief Manufacturing Officer at Assembly Biosciences, Inc. She started this position in 2022.
Prior to her current role, she worked at Gossamer Bio, Inc. as the Senior Director & Head-Process Chemistry from 2019 to 2020.
Before that, she was the Director-CMC at Abide Therapeutics, Inc. from 2017 to 2018.
Nicole's earliest position was as a Principal at Gilead Sciences, Inc. from 2009 to 2015.
She holds a doctorate degree from the University of California, Irvine and an undergraduate degree from the University of California San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/04/2024 | 13 025 ( 0,24% ) | 174 014 $ | 30/04/2024 |
Postes actifs de Nicole White
| Sociétés | Poste | Début |
|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 17/11/2020 |
Anciens postes connus de Nicole White
| Sociétés | Poste | Fin |
|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | 01/11/2020 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/04/2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/10/2015 |
Formation de Nicole White
| University of California, Irvine | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
